CDK4 and ovarian carcinoma: The SY-1365 trial was designed to target specific cohorts of patients with resistance to prior treatments, including platinum resistance in ovarian cancer and CDK4/6 inhibitor plus aromatase inhibitor resistance in HR+ breast cancer (Table 4).